SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma gets USFDA approval for Voriconazole Tablets

26 May 2016 Evaluate

Ajanta Pharma has received final approval for Voriconazole Tablets (50mg & 200mg) from the US Food and Drug Administration (FDA). Voriconazole is a triazole antifungal for treatment of serious invasive fungal infections and the generic version of Vfend.

Voriconazole Tablets is part of ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US FDA has granted Ajanta Pharma 10 ANDA final approvals and 2 tentative approvals. An additional 14 ANDAs are under review with FDA.

Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.

Ajanta Pharma Share Price

3177.90 -75.80 (-2.33%)
25-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.15
Dr. Reddys Labs. 1350.00
Cipla 1440.30
Zydus Lifesciences 1101.50
Lupin 2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: